Pravastatin and placental insufficiency associated disorders: A systematic review and meta-analysis
Conclusion: Pravastatin treatment prolonged pregnancy duration and improved associated obstetrical outcomes in pregnancies complicated with uteroplacental insufficiency disorders in cohort studies.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/ identifier CRD42020165804 17/2/2020. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - November 9, 2022 Category: Drugs & Pharmacology Source Type: research
Pravastatin Reduces Matrix Metalloproteinases Expression and Promotes Cholesterol Efflux in Osteoarthritis Chondrocytes
CONCLUSION: Pravastatin can reduce the expression of MMPs in IL-1β-induced human chondrocytes and protect the chondrocyte matrix. The mechanism may be related to promoting the expression of proteins related to the cholesterol efflux pathway and reducing the level of cellular cholesterol.PMID:36276856 | PMC:PMC9584666 | DOI:10.1155/2022/9666963 (Source: Evidence-based Complementary and Alternative Medicine)
Source: Evidence-based Complementary and Alternative Medicine - October 24, 2022 Category: Complementary Medicine Authors: Yunpeng Wu Xuezhou Li Yongyuan Guo Yuhua Jia Pengfei Sun Source Type: research
A Randomized Pilot Clinical Trial of Pravastatin Versus Placebo in Pregnant Patients at High Risk of Preeclampsia
(Am J Obstet Gynecol. 2021;225:666.e1–15) (Source: Obstetric Anesthesia Digest)
Source: Obstetric Anesthesia Digest - September 1, 2022 Category: Anesthesiology Tags: Mother, Fetus, Neonate Source Type: research
